420 with CNW — Why New Jersey Legislators Are Unwilling to Allow Patients to Grow Medical Cannabis

New Jersey legislators are currently in the process of finalizing the details of the state’s marijuana decriminalization and legalization policies. While the S3550 bill has lessened the penalties for individuals found carrying less than six ounces of marijuana, it still forbids any person from having the intent to distribute or the distribution and possession of a controlled and dangerous substance. The bill does not touch on marijuana home-cultivation, which remains criminalized.

This is despite poll data from a Rutgers University 2018 poll, showing that 60% of voters in the state disagreed with a prohibition that forbade residents from cultivating their own marijuana at home.

There are still many gaps in the bill, despite the work that’s been poured into the legislative sessions. Ryan Magee, a marijuana attorney at Riker Danzig Scherer Hyland & Perretti, ascribes this to how much support and time is available to sufficiently address the topic. Magee goes further to state that if at-home growing is ignored this time around, reform may happen in the future.

More than a decade ago, legislators had discussed home cultivation of marijuana while drafting the state’s medical cannabis program. While it wasn’t included in the Compassionate Use for Medical Marijuana Act’s final draft, which was signed by Gov. Jon Corzine, there once had been a home cultivation provision that allowed registered patients to cultivate up to six plants at home without incurring any penalty.

However, opponents had compared New Jersey’s proposed initiative with California’s proposition 215, which allowed medical patients to cultivate marijuana at home. At the time, California was the first state to implement a state-regulated medical cannabis program, a move that garnered widespread criticism.

To avoid this, the sponsors of the bill shifted their decision-making power to the state’s health department. This decision led to the department limiting the amount of usable cannabis a patient could have to an ounce per month. Soon after this, the assembly health committee removed the provision allowing home cultivation from the bill completely.

This came soon after state Sen. Nicholas Scutari supported the pardon of John Jay Wilson, who was a multiple sclerosis patient, to grow his own marijuana.

In addition to Washington, DC, 17 states in the U.S. currently permit at-home marijuana cultivation for individuals aged 21 and above. However, some states have imposed more limitations on which residents can cultivate at home.

For instance, in Arizona and Nevada, residents who are of age are allowed to cultivate marijuana recreationally only if they live no less than 25 miles away from a dispensary. In Missouri, the law dictates that only medical cannabis patients are allowed to cultivate at home, and these cannabis patients must pay a $100 fee.

States such as Massachusetts and Alaska have more progressive measures. Massachusetts allows growing of up to 12 plants if there are two residents of age in the household while Alaska allows any individual who is 21 years and older to grow up to six marijuana plants.

Meanwhile, Canada legalized cannabis several years ago, and its market is reaching maturation. This phase is marked by specialization, and Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) has staked claim to the number-one spot in the cannabis extracts segment, a niche worth nearly $3 billion annually in Canada.

NOTE TO INVESTORS: The latest news and updates relating to Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) are available in the company’s newsroom at https://cnw.fm/PULL

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — Study Shows Medical Marijuana Beneficial to Parkinson’s Patients

The health and medical field is seeing an increased interest in the use of medical marijuana to reduce symptoms of various ailments such as Parkinson’s disease, now that the herb has been legalized in many regions across the globe.

Results from a survey of Parkinson’s disease patients from Germany show that more than 8% of patients with the disease admitted to using marijuana products and more than half of those users, who made up roughly 54%, revealed that the products had been clinically beneficial.

Marijuana products that contain THC, which is the primary psychoactive compound in marijuana, are allowed to be prescribed in Germany when marijuana can help alleviate disabling symptoms and when prior therapies have not been tolerated by the patient or have been unsuccessful.

On the other hand, products containing pure cannabidiol (“CBD”), which is extracted from the hemp plant directly, are available on the internet as well as in pharmacies, and can be acquired without a prescription.

The researchers’ objective was to evaluate patients’s perceptions of medical marijuana while also assessing the experiences of patients who had already used marijuana products. They carried out a cross-sectional countrywide questionnaire-based survey among German Parkinson’s association members.

The association, Deutsche Parkinson Vereinigung, is the largest group of Parkinson’s disease patients, made up of about 21,000 members from German-speaking nations. The questionnaires were distributed in April 2019, both in the investigator’s clinic and with the group’s membership journal.

The researchers analyzed more than 1,300 questionnaires, with their results showing that the interest in medical marijuana in the Parkinson’s disease community was high. However, knowledge on different types of marijuana products was scanty. From the study population, only 9% of the respondents could differentiate between CBD and THC, 28% were informed on the different routes of administration, i.e., oral administration vs. inhaling, and 51% knew of medical marijuana’s legality.

The researchers found that tolerability was good, with 40% of the marijuana product users reporting that they helped alleviate muscle cramps and pain. Additionally, more than 20% of the users revealed a decrease in restless legs, anxiety, depression, tremors, freezing and a decline of stiffness.

Besides this, patients also reported that as compared to oral products which contained CBD, inhaled marijuana products that contained THC were more effective in remedying stiffness. However, those products were not well tolerated.

Dr. Carsten Buhmann, who was involved in the study, explained that the study’s findings confirmed that patients with Parkinson’s disease had a growing interest in treatment with medical marijuana but had limited knowledge on how to take it and how to differentiate between CBD and THC.

Buhmann then remarked that physicians should consider these angles when giving advice to their patients on treatment with medical marijuana. The findings, he said, may assist physicians in deciding on the type of cannabinoid a patient may benefit from, whether a patient could benefit from the treatment, the symptoms it may address as well as the suitable course of administration.

It should be remembered that cannabis medicines come in different forms, and extracts are fast becoming the go-to favorite among those forms. In Canada, Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) is the undisputed leader in the extracts segment, which is estimated to have an annual value of $2.7 billion.

NOTE TO INVESTORS: The latest news and updates relating to Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) are available in the company’s newsroom at https://cnw.fm/PULL

About CNW420

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — How Will CBD Impact Your Work Performance?

A significant amount of research has been done on the different ways that various cannabinoid formulations can affect an individual’s driving skills, telephone or computer skills, memory or even work productivity.

However, as researchers do not know the exact cannabinoid that may cause any concerning issues, they do admit that it is likely that CBD may impact any of these areas mentioned above. You should therefore exercise remarkable caution when indulging in order to maintain a positive work environment.

Further studies on cannabinoids and how they affect IQ and memory have shown that no significant changes in IQ have been observed.

The first study to suggest a decrease in IQ was a British study that found that a seven-point drop in IQ was observed when individuals use cannabinoids daily. However, a subsequent study conducted in New Zealand found no notable change in an individual’s IQ.

Latter findings received more support from another study that was conducted in the United States which not only had a greater number of participants than the former studies combined but also had a number of identical twins. The researchers in the U.S. study found no change in IQ in the identical twin pairs when one of the twins was not using cannabinoid formulations while the other was.

However, it should be noted that significantly heavy use of CBD formulations may bring about changes in an individual’s memory. If you are experiencing issues with your short-term memory, studies show that short-term memory deficits resolve in about three weeks. Recent data suggests that an individual’s memory function will return seven days after cessation of consuming a cannabinoid formulation.

When it comes to driving, one should never drive under the influence of any mind-altering substance, including drugs and alcohol. However, one company holds 55,000 patient-years supporting their product, which demonstrates no increased risk of parking tickets or motor vehicle violations when on different cannabinoid formulations.

Despite this though, it’s still hard to say whether cannabinoids contribute to any risk when it comes to driving.

Other individuals may also be concerned about how CBD impacts their telephone and computer skills. CBD isn’t a psychoactive, meaning it can’t get a user high as marijuana does. It may, however, result in a sense of calm. Researchers hypothesize that no measurable difference is observed with regard to either of the above skills when use of cannabinoids is considered. While some subtle changes are noted, those changes are dependent on how well individuals have memorized their jobs and also how long individuals have been at their jobs.

Speaking of cannabinoids, Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) has established itself as a market leader in the Canadian extracts segment of the cannabis industry. The company is now offering its services to other licensed entities within and beyond Canadian borders.

NOTE TO INVESTORS: The latest news and updates relating to Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) are available in the company’s newsroom at https://cnw.fm/PULL

About CNW420

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.